Quick Answer
NOVAVAX INC reported Research And Development Expense of $342.32 million for the year ending 2025.
- NOVAVAX INC showed a decrease of -12.5% in Research And Development Expense from 2024 to 2025.
- This data is from NOVAVAX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NOVAVAX INC's Research And Development Expense has grown by 1,227.9%.
- Historical annual values: Fiscal year 2025: $342.32 million | Fiscal year 2024: $391.17 million | Fiscal year 2023: $737.50 million | Fiscal year 2022: $1.24 billion | Fiscal year 2021: $2.53 billion | Fiscal year 2020: $747.03 million | Fiscal year 2019: $113.84 million | Fiscal year 2018: $173.80 million | Fiscal year 2017: $168.44 million | Fiscal year 2016: $237.94 million | Fiscal year 2015: $162.64 million | Fiscal year 2014: $94.42 million | Fiscal year 2013: $58.53 million | Fiscal year 2012: $26.91 million | Fiscal year 2011: $18.36 million | Fiscal year 2010: $28.03 million | Fiscal year 2009: $25.78 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: